NIH Funding: Pitting Young Investigators Against Senior Scientists
.jpg)
The competition for National Institutes of Health (NIH) grant funding has been intensifying over the past five years or more. In the past, NIH had gone to extraordinary lengths to insure that senior investigators didn’t lose their funding so as to not hinder the progress of long standing research programs. However, in recent years, NIH funding managers have eschewed the unwritten policy of preferentially funding established investigators in favor of younger ones! According to an article in today’s New York Times, NIH grant managers are increasingly ignoring the advice of study sections and funding scientists whose projects receive less favorable reviews than those denied money. Many of the favored funding recipients are “new investigators,” or scientists who had never before received a grant from NIH. Further, in 2007, the last year for which figures are available, “19 percent of the grants awarded to individual scientists were made as exceptions, or given outside of rankings by scientific reviewers, according to a report by the Government Accountability Office. Nearly all of the increase in exceptions in 2007 went to new investigators, with the young scientists’ share rising from 20 percent of all exceptions in 2003 to half in 2007.”
Not surprisingly, many senior investigators are calling “foul” despite the fact that the median age at which scientists win their first NIH grant has risen steadily, to 41 years, from 35 in 1980. While all meritorious grant proposals ought to be funded, the reality is that there simply isn’t enough money to around. As a former tenure track faculty member, I believe that new investigators deserve something of a handicap or edge when it comes to competing for their first grants. After all, how can an overwhelmed, newly minted faculty member be expected to successfully compete with established investigators who have mastered their jobs and more importantly, the art of grant writing? Sadly, the old practice of preferentially funding established investigators over new ones tended to stifle innovation and reward scientists who liked to play it safe!
We live in an increasingly competitive world where innovation is at a premium. American scientists and granting agencies must abandon their old practices if they want to remain competitive on the world stage. To that end, funding some young, innovative investigators over a few established faculty members who have enjoyed long successful scientific careers doesn’t seem like a bad investment to me! After all isn’t all about retun on investment these days?
Until next time...
Good Luck and Good Job Hunting!!!!
The appearance of the Swine Flu aka H1N1 last spring not only created a worldwide panic, it demonstrated to Albert Osterhaus, head of virology at the Erasmus Medical Center in the Netherlands how uninformed the lay public was about viral outbreaks, epidemiology and public health. This prompted Dr. Osterhaus and his colleagues to create a free, online video game called the 
Despite dire predictions, the biotechnology industry appears to be weathering the recession better than most. According to a
For those of you interested in the Canadian biotechnology scene I want to mention a good resource that I came across recently. The Canadian BioTechnologist 2.0 Blog (
In the February issue of 
For the past 60 years, American science was second to none. However, the US is perilously close to losing that distinction. Put simply, American science, like its economy, is in free fall.
